|
MRI to Detect Breast Tumors in Women Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about MRI to Detect Breast Tumors in Women conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. MRI to Detect Breast Tumors in Women Clinical research trials and MRI to Detect Breast Tumors in Women health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like MRI to Detect Breast Tumors in Women. MRI to Detect Breast Tumors in Women Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a MRI to Detect Breast Tumors in Women clinical trial. Subjects frequently get the best healthcare possible for their MRI to Detect Breast Tumors in Women condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "M" Clinical Trials Conditions > MRI to Detect Breast Tumors in Women  MRI to Detect Breast Tumors in Women
MRI to Detect Breast Tumors in Women
For Condition: Breast Cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , University of Pennsylvania Cancer Center
Synopsis: RATIONALE: New imaging procedures, such as MRI, may improve the ability to detect breast tumors. PURPOSE: Diagnostic study to determine the value of MRI in detecting breast tumors in women who have had suspicious mammographic or clinical examinations.
Details: OBJECTIVES: I. Evaluate the performance of breast magnetic resonance imaging (MRI) in conjunction with mammography for the detection and characterization of lesions in women with suspicious mammographic or clinical examinations. II. Assess the incremental value of breast MRI to determine the local extent of cancer in these patients. III. Assess the value of breast MRI to determine the prevalence and characteristics of incidental enhancing lesions in the remainder of the breast. PROTOCOL OUTLINE: This is a multicenter study. Patients undergo a high resolution 3D post contrast magnetic resonance imaging (MRI) scan. Patients with enhancing abnormalities undergo a dynamic scan no less than 18 hours later. Some patients may require a third scan if a core biopsy is to be performed. Patients who are ultimately found to have cancer are assessed for extent of cancer including measurement of the index lesion and identification of other present foci of cancer in relation to the index lesion. Further histological diagnosis of index lesions is determined by MRI-guided needle localization excisional biopsy. Patients with benign needle biopsy are followed for 2 years. Patients with benign primary lesions receive a follow up MRI scan 1 year after the initial scan. Patients with benign primary lesions and incidental enhancing lesions (IEL) are followed at 2 years. Patients with negative needle biopsies not yielding a specific diagnosis and who do not undergo subsequent excisional biopsy are followed yearly for 2 years. PROJECTED ACCRUAL: A total of 1500 patients will be accrued for this study over 4.25 years.
Eligibility:
Study Type: Interventional, Diagnostic
Minimum Age/Maximum Age: 18 Years/79 Years
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Suspicious mammographic finding or palpable abnormality OR Suspicious clinical or ultrasound finding without associated benign mammographic features - May have more than one suspicious lesion based on mammography or clinical exam if an index lesion is present - Mammogram within 2 months prior to MRI scan and copy of films required of all patients 30 years of age and over - Eligibility maintained if patient meets above criteria and has had: Breast implant; Prior benign excisional or core biopsy at least 6 months prior to study; Fine needle aspiration performed at any time; Cancer in the contralateral breast - No history of prior breast cancer in the study breast - No benign excisional or core biopsy of the affected breast within the last 6 months --Prior/Concurrent Therapy-- - Not specified --Patient Characteristics-- - Age: 18 to 79 - Sex: Women - Performance status: Not specified - Life expectancy: Not specified - Hematopoietic: Not specified - Hepatic: Not specified - Renal: Not specified - Cardiovascular: No implanted pacemaker - Other: No implanted ferromagnetic device; No ferromagnetic aneurysm clip; No severe claustrophobia; No ocular metal fragments; No schrapnel injury; No difficulty lying prone; No poor venous access; No impaired decision-making abilities; Not pregnant
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MitchellSchnall, Study Chair, University of Pennsylvania Cancer Center
Universitaetskliniken Bonn
Bonn, , D-53127
Germany
Simmons Cancer Center - Dallas
Dallas, Texas, 75235-9154
United States
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
Roswell Park Cancer Institute
Buffalo, New York, 14263-0001
United States
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, 27599-7295
United States
Martin Luther Universitaet
Halle Saale, , DOH-0-6112
Germany
University of Colorado Cancer Center
Denver, Colorado, 80010
United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
United States
University of Toronto
Toronto, Ontario, M5S 1A8
Canada
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030-4009
United States
Cancer Center at the University of Virginia
Charlottesville, Virginia, 22908
United States
Johns Hopkins Oncology Center
Baltimore, Maryland, 21231-2410
United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
United States
UCSF Cancer Center and Cancer Research Institute
San Francisco, California, 94143-0128
United States
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, 19104-4283
United States
Additional Information:
Study ID Numbers: CDR0000066242; UPCC-ACR-6883
Study Start Date: May 1998
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003302
Other Breast Cancer Studies:
1. Exemestane and Raloxifene in Treating Postmenopausal Women With a History of Ductal Carcinoma in Situ, Stage I, Stage II, or Stage III Breast Cancer
2. Primary Chemotherapy with Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer
3. Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
4. A Phase I Study of Infusional Paclitaxel with the P-Glycoprotein Antagonist PSC 833
5. Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Related Studies:
Other Breast Cancer Clinical Trials
Other Arkansas Clinical Trials
Other Little Rock Clinical Trials
MRI to Detect Breast Tumors in Women
|
|
|
|
|
|
|
|
